← Back to Clinical Trials
Recruiting NCT06362733

NCT06362733 Modified Pivotal Response Treatment for Insistence on Sameness in Autistic Youth

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06362733
Status Recruiting
Phase
Sponsor Stanford University
Condition Autism Spectrum Disorder
Study Type INTERVENTIONAL
Enrollment 44 participants
Start Date 2024-07-11
Primary Completion 2026-07-01

Eligibility & Interventions

Sex All sexes
Min Age 4 Years
Max Age 17 Years
Study Type INTERVENTIONAL
Interventions
Modified Pivotal Response Treatment for Insistence on Sameness in Autistic Youth

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 44 participants in total. It began in 2024-07-11 with a primary completion date of 2026-07-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this open label trial is to examine the preliminary feasibility, acceptability, and effectiveness of a 12-week behavioral intervention program (1 hour/week) to treat insistence on sameness (e.g., difficulty tolerating changes in routine) in youth with autism spectrum disorder (ASD). Treatment will be delivered via secure telemedicine platform and consist of a combination of parent-training and parent-mediated intervention with the child.

Eligibility Criteria

Participants will include children with: 1. parent/guardian aged 18 years or older with a child aged between 4.0 to 17.11 years old at the time of parental consent; 2. diagnosed with ASD (based on history, review of available medical records including diagnostic testing, e.g., ADOS) or suspicion of ASD diagnosis and confirmed with Autism Diagnostic Interview-Revised (ADI-R); 3. parent-reported clinically significant concerns regarding insistence on sameness and behavioral inflexibility; 4. stable behavioral and pharmacological treatment for at least two weeks with no anticipated changes; 5. English-speaking parent and youth able to consistently participate in study procedures; 6. family resides in United States.

Contact & Investigator

Central Contact

Emily Ferguson, PhD

✉ eferguso@stanford.edu

📞 650-736-1235

Principal Investigator

Antonio Hardan, MD

PRINCIPAL INVESTIGATOR

Stanford University

Frequently Asked Questions

Who can join the NCT06362733 clinical trial?

This trial is open to participants of all sexes, aged 4 Years or older, up to 17 Years, studying Autism Spectrum Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06362733 currently recruiting?

Yes, NCT06362733 is actively recruiting participants. Contact the research team at eferguso@stanford.edu for enrollment information.

Where is the NCT06362733 trial being conducted?

This trial is being conducted at Stanford, United States.

Who is sponsoring the NCT06362733 clinical trial?

NCT06362733 is sponsored by Stanford University. The principal investigator is Antonio Hardan, MD at Stanford University. The trial plans to enroll 44 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology